TY  - JOUR
AU  - Moraitis, Alexandros
AU  - Prochnow, Andre
AU  - Poeppel, Thorsten Dirk
AU  - Schmitz, Jochen
AU  - Laschinsky, Christina
AU  - Herrmann, Ken
AU  - Bockisch, Andreas
AU  - Fragoso Costa, Pedro
AU  - Kersting, David
AU  - Jentzen, Walter
TI  - Tumor Dose-Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET.
JO  - Journal of nuclear medicine
VL  - 66
IS  - 4
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2025-00570
SP  - 641–647
PY  - 2025
N1  - 66(4), pp. 641–647
AB  - [131I]Metaiodobenzylguanidine (MIBG) therapy in patients with neural crest tumors has demonstrated sustained control of catecholamine-associated hypertension and corresponding partial response. Details on how neural crest tumors respond to an absorbed dose delivered by [131I]MIBG-targeted therapies is insufficiently known. The primary aim of this retrospective study was to assess the tumor dose-response relationship by means of quantitative analysis of [124I]MIBG PET data. Methods: The tumor dose-response relationship was studied in patients with advanced malignant pheochromocytoma, neuroblastoma, or paraganglioma receiving [131I]MIBG treatment, as well as pretherapeutic and follow-up [124I]MIBG-based dosimetry. [124I]MIBG PET imaging was performed around 4, 24, 48, and 120 h after injection. Lesion uptake was projected to [131I]MIBG for every time point, and respective time-integrated activity coefficients (TIACs) for [131I]MIBG were calculated and used for tumor-absorbed dose estimation. Functional response was denoted for decrease of maximal lesion uptake or TIAC by at least 30
KW  - PET (Other)
KW  - [124I]MIBG (Other)
KW  - [131I]MIBG (Other)
KW  - dose response (Other)
KW  - neural crest tumor (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40081949
DO  - DOI:10.2967/jnumed.124.269377
UR  - https://inrepo02.dkfz.de/record/299833
ER  -